INTRODUCTION AND OBJECTIVES: Erectile dysfunction (ED)
in kidney transplant patients is not uncommon. The ideal treatment modality should not interfere with the graft function. Low-intensity Shock Wave Therapy Extracorporeal (Li-ESWT) has been of interest due to its angiogenic properties and has shown interesting results when used to treat patients with cardiovascular disease and non-transplanted men with ED. Our objective is to study the efficacy and safety of Li-ESWT for the treatment of ED in kidney transplanted men of probable vascular etiology.
METHODS: Twenty men (mean age [ 53.7 years, range 46 to 61 years ) that have been submitted to kidney transplant for at least 6 months and have been suffering from ED for at least 6 months were selected for the treatment. This was a double-blinded, single-center, prospective, randomized, sham-controlled trial. The ESWT protocol was based in a 2 treatment sessions per week for 3 weeks.The sham treatment was performed using the same device replacing the effective probe for one that emits zero energy, but delivers a sound and pulse sensation during treatment. Follow-up assessment was performed with International Index of Erectile Function Questionnaire (IIEF) score and Erection Hardness Score (EHS) after 1, 4 and 12 months.
RESULTS: A total of 20 patients were recruited into the study. 10 patients were randomized into the sham therapy arm and 10 patients into the Li-ESWT arm. Groups were similar regarding the baseline IIEF score and EHS. IIEF score improvement was higher than 5 in 70% (ranged from 0-10) and in 10% (ranged from 1-14) in Li-ESWT and Sham groups, respectively. IIEF and EHS improvement were statistically significant in Li-ESWT group, p <0,0001. The mean change in IIEF score after 12 months was 4.8in Li-ESWT group. Data is illustrated in Graphic 1.
CONCLUSIONS: Li-ESWT is a non pharmacological treatment with clinical efficacy. Besides its rehabilitative potential, this treatment is feasible, tolerable and effective. Further studies are needed to determine the optimal treatment protocols. The treatment of chronic pelvic pain syndrome (CPPS) is still discussed since its multifactorial pathogenesis. Several treatment modalities including antimicrobial drugs, muscle relaxants, a-blockers, biofeedback physical therapy such as monotherapy or combination therapy have been proposed and investigated. Recently, many reports have indicated that extracorporeal shock-wave therapy (ESWT) for CPPS can significantly improve the symptoms of pelvic pain and urination. The aim of the study is to evaluate the effects of combining transperineal ESWT and therapy (anti-inflammatory and antibiotics), versus therapy alone for the treatment of non-inflammatory CPPS METHODS: From April 2017 to April 2018, 125 consecutive patients were treated with ESWT þ therapy or therapy alone. Adjustment variables consisted of age and IPSS questionnaire at baseline using 1:1 propensity-score matching. Overall, 32 patients were considered subdivided into the following: 16 patients who received ESWT þ therapy (group A) and 25 who received therapy alone (group B). Patients were administered ESWT with protocol treatment of one session per week for 8 weeks, 3000 shockwaves with 0.25 mJ/mm2 of energy and 5 HZ of frequency.
RESULTS: Overall, the mean age was 52.7 (SD 13.7), mean IPSS was 16.8 (SD 5.37), mean IPSS-QoL was 3.75 (SD 0.9), mean prostate volume was 35.8 (SD 15.4) and mean peak flow was 9.7 (SD 2.3). The mean change of IPSS was -5.75 (SD 4.31) in Group B and -9.81 (SD 5.06) in Group A (p[0.04) and the mean change of IPSS-QoL was -1.0 (SD 1.59) and -3.4 (SD 0.63) (p[0.04) while the difference for Qmax was not statistically different (-6.8 vs. -6.5; p[0.7) .
CONCLUSIONS: Based on the findings of this a populationbased propensity score adjusted analysis ESWT þ therapy was superior than therapy alone in ameliorating symptoms and quality of life. Although the design was not a randomized study, the propensity score matching is able to estimate the effect of a treatment by accounting for the covariates that predict receiving the treatment. These translate our findings into clinical practice with high level of evidence but should be confirmed with greater sample size.
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PD21-09 DAILY TADALAFIL THERAPY: A NEW TREATMENT OPTION FOR PEYRONIE'S DISEASE?
Hyun Jun Park*, Sung Woo Park, Tae Nam Kim, Busan, Korea, Republic of INTRODUCTION AND OBJECTIVES: It has been speculated that phosphodiesterase type 5 inhibitors may have an effect on Peyronie's disease (PD) by inhibiting tissue remodeling after acute injury and decreasing the oxidative stress responsible for inflammation and fibrosis. This study evaluated the efficacy of tadalafil in patients with PD.
METHODS: 66 patients diagnosed with PD were divided into three groups. Group 1 (20 patients) were treated with an intralesional injection of verapamil (IVI); group 2 (23 patients) were treated with 5 mg tadalafil once daily, and group 3 (23 patients) were administered IVI and
